Redeye comment on the Xvivo Heart preservation study now under way. The first patient was transplanted during November as the first in a study that will include 202 patients and focus on the new device's safety and efficacy. The primary objective of the study is to discover if the device improves transplant results. We see this as a positive and important step in the heart transplant field for Xvivo. Our initial estimation was that this study would start during the third quarter; however, this is only a minor delay considering the current conditions. We have calculated a launch in 2024, which is still feasible. At this point, we are not making any adjustments to our estimates as this development was expected.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se